SCHEMBL21180447

SCHEMBL21180447

CCc1ccc(C(C)N)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
TP53 P04637 1/20 0.60
HTT P42858 1/20 0.60
PNMT P11086 2/20 0.47
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 1/20 0.41
NFKB1 P19838 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GLA P06280 1/20 0.40
CSNK2A1 P68400 3/20 0.39
PDE2A O00408 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
ESR1 P03372 1/20 0.37
TRPA1 O75762 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10163053 0.84 CYP1A2 (0.42) LMNATP53HTTPNMTCYP1A2
SCHEMBL14469639 0.83 LMNA (0.58) LMNATP53HTTPNMTCYP1A2
SCHEMBL18075635 0.81 PDE2A (0.51) LMNATP53HTTPNMTCYP1A2
SCHEMBL24685760 0.81 PNMT (0.39) LMNATP53HTTPNMTCYP1A2
SCHEMBL18103191 0.81 PNMT (0.39) LMNATP53HTTPNMTCYP1A2
SCHEMBL18266512 0.78 LMNA (0.38) LMNATP53HTTCYP1A2ALDH1A1
SCHEMBL12808595 0.78 LMNA (0.38) LMNATP53HTTCYP1A2ALDH1A1
SCHEMBL8205123 0.77 LMNA (0.37) LMNATP53HTTCYP1A2ALDH1A1
SCHEMBL3899828 0.75 TP53 (1.00) LMNATP53HTTPNMTCYP1A2
SCHEMBL5492924 0.75 TP53 (1.00) LMNATP53HTTPNMTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3270926-B1 TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2021-08-04 EP disclosed
US-10358435-B2 Triazolyl pyrimidinone compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10358435-B2 Triazolyl pyrimidinone compounds as PDE2 inhibitors PDE2A, PDE12, PDE4D LMNA 4687/4885TP53 4183/4885HTT 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.